Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A middle-aged woman without any symptoms of ectopic hormone production underwent a right-sided mastectomy for infiltrating ductal carcinoma. She later developed axillary lymph node metastases which were somewhat carcinoid-like. This prompted further investigation, when scattered argyrophilic endocrine cells were found in both the primary tumour and its metastases. The endocrine cells reacted immunocytochemically with antisera against ACTH and HCG. Despite the endocrine activity of the tumour, it was still regarded as a ductal carcinoma since the endocrine cells constituted the minority cell population. The present study indicates strongly that ectopic hormone production in association with carcinoma of the breast is a result of hormone synthesis and release by the tumour cells.
 ...
PMID:Argyrophil endocrine cells with ACTH and HCG immunoreactivity in a carcinoma of the breast. 613 18

With the object of studying the possible usefulness of the simultaneous plasma determination of CEA, HCG-beta and beta 2-microglobulin in patients with nontrophoblastic tumors, we measured by radioimmunoassay the concentrations of these substances in 77 patients with normal renal function. In the group without metastases (32 cases), the percentages of positives we low and similar for the 3 tumor markers. In the group with metastases (45 cases), the X2 test of independence between each of the 2 markers at a level of 95 % showed a relationship between the results obtained in the determination of HCG-beta and beta 2-microglobulin, as an independence between CEA and HCG-beta results and CEA and beta 2-microglobulin results. These data suggest the utility of determining CEA with only 1 of the other 2 antigens in disseminated tumors.
 ...
PMID:Simultaneous plasma determination of CEA, HCG-beta and beta-2-microglobulin in patients with nontrophoblastic tumors. 616 Jun 67

74 patients with disseminated non-seminomatous testicular cancer were randomly entered on a prospective sequential combination chemotherapy regimen with mandatory crossover, consisting of either vinblastine/bleomycin or adriamycin/cis-dichlorodiammineplatinum (II) (DDP) as initial therapy. Independent of the randomization the overall remission rate in 71 evaluable patients was 89% including 54% complete remissions. 35% of the patients remained disease-free at 2+ to 28+ months with a median of 12 months. By additional surgical removal of residual pulmonary metastases in two patients the complete remission rate was increased to 40/71 (56%), and the number of patients with no evidence of disease to 27/71 (38%). According to the life-table method the two-years survival rates were 63% for complete responders and 29% for all other patients, which was significantly lower. 53 patients (75%) were alive at 3 to 28 months with a median of 9 months. Additional advanced abdominal disease, initially elevated beta-HCG and LDH and extension of pulmonary disease were of significant negative influence on the prognosis. The evaluation of single chemotherapy courses revealed equal efficacy of both combinations. However, response to adriamycin/DDP occurred in 46% of the courses, when vinblastine/bleomycin had failed, while response to vinblastine/bleomycin occurred only in 21% of the courses when adriamycin/DDP had failed. Thus different patterns of cross-resistance between these alternative regimens may exist.
 ...
PMID:[Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum (II) in non-seminomatous testicular cancer. I. Results of a prospective randomized phase III-study with 71 patients with disseminated disease (stage IV) (author's transl)]. 616 Dec 73

Thirty patients with nonseminomatous testicular cancer and no evidence of metastases outside the retroperitoneum were evaluated for discrepancy between the clinical and pathologic stages and also for frequency of elevations of the serum levels of human chorionic gonadotropin (hCG) and alphafetoprotein (AFP). When marker-level data were not considered in the staging, the clinical and pathologic stages differed in 47% of the patients; the inclusion of marker data reduced the staging error to 37%. Seven of ten patients with clinical Stage I, pathologic Stage II disease had normal marker levels (false-negative results). However, there were no false-positive results: abnormal marker levels before retroperitoneal lymphadenectomy always signalled persistent tumor unless the level could be accounted for by the metabolic decay rate of marker produced by the primary tumor. Comparison of marker-level data from these patients with data from 48 patients with Stage III disease demonstrated increasing frequency of elevated marker levels with increasing stage (P less than 0.001). Serial determinations of HCG and AFP are helpful in clinical staging and are necessary in clinical management.
 ...
PMID:Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. 616 91

Tumor markers are a major part of the secondary prevention (detection) efforts. There are major logistic and economic constraints which could be overcome if a simple laboratory test could be devised that would (based on a sample of blood or urine) indicate the presence of cancer--with a high degree of specificity and sensitivity--before there are metastases. Hence, it could serve as an acceptable screening test for initiating definitive diagnostic procedures with a goal of making an "early diagnosis:" that is, a diagnosis before metastasis has occurred, and when simple removal of the tumor would result in normal survival characteristics for a population of patients. No such test exists, although extensive efforts have been made and a number of tumor markers have been described and tested. To date, no combination of markers has been found that meets the criteria set. Tumor markers have principally been used to monitor therapy, i.e., predict outcome or signal a recurrence. Most of the markers described fall into the classes of oncofetal antigens (CEA), (alpha-fetoprotein)-hormonal products (HCG, ACTH), enzymes, and the polyamines. There are several recent books devoted to tumor markers. The major features will be reviewed.
 ...
PMID:Tumor markers in cancer prevention and detection. 616 53

Representation of the clinical significance of the tumor markers CEA, HCG-beta and alpha 1-fetoprotein (AFP) of the basis of the relevant literature and of own studies. As a marker for tumors of the urogenital tract, CEA is at present of very little value as it is too unspecific. HCG-beta and AFP, on the other hand, are important new parameters for both the demonstration of so-called subclinical metastases (staging) and clinical case control, particularly with malignant nonseminomatous tumors of the testicles. Over a period of four years we found in 62 out of 85 patients with nonseminomatous testicle tumors that -- in accordance with the literature -- simultaneous determination by the two markers (85% positive) is decidedly superior to the determination by one marker only. Out of 23 patients with a histologically classified seminoma, one patient (i.e. 4.4%) was HCG-beta positive. So far, the prognostic significance of such findings has generally not been clarified. It is shown here that exclusively "marker-oriented" therapy planning and case control without the clinical examination methods used so far are not yet justified because of the inadequate specificity and sensitivity of these two markers as well as of more recent ones (SP-1, TPA). Nevertheless, HCG-beta and AFP are at present important new methods in the areas of diagnosis (staging), therapy planning and case control as primarily increased marker values, or marker values increased during or after therapy clearly indicate metastasizing or renewed tumor activity, respectively.
 ...
PMID:[CEA, HCG-beta and alpha fetoproteins - clinical significance as tumor markers]. 616 86

Based on combination chemotherapy with vinblastine, bleomycin, cisplatin, ifosfamide, etoposide and adriamycin--these appear to be the most active agents--complete remissions between 60 and 70% of all patients with disseminated testicular teratomas appear realistic. Extent of disease, distribution and localization of metastases, patterns of specific markers such as alpha fetoprotein and beta-HCG, and the general condition of the patient at initiation of therapy determine the final prognosis. It appears most important that induction chemotherapy needs to be as intensive as possible: individualized doses and short intervals should be used initially despite some toxicity associated with this approach. In regional disease, four to six courses of adjuvant chemotherapy after lymphadenectomy have yielded cure rates as high as 95% (Stage II A) and 70% (Stage II B), respectively.
 ...
PMID:[Progress in the therapy of testicular teratoid tumors]. 618 1

Clinical details of 85 men presenting with previously untreated metastatic seminoma are presented. In Stage II disease relapse rate was related to the size of metastases. In IIA (32 patients) the relapse rate was 9.4%; IIB (11 patients), 18.2%; and IIC (23 patients), 39.1%. The continuous disease-free survival rate was significantly worse for IIC than IIA and IIB patients (P = 0.023). No instance of first relapse in supradiaphragmatic nodes was observed in 13 men with Stage II disease treated with irradiation limited to infradiaphragmatic nodes. In relapsing Stage IIC patients, extralymphatic metastasis was as frequent as abdominal relapse. On the basis of these observations, together with preliminary data in nine men receiving Cis-platinum-containing chemotherapy, all of whom are in complete remission, it is proposed that patients with Stage IIA and IIB disease should receive infradiaphragmatic irradiation with chemotherapy deferred until relapse. Stage IIC patients should receive chemotherapy initially, followed by irradiation. In Stage III and IV disease chemotherapy should be initial therapy with radiotherapy for bulky disease on an individualised basis. Moderate elevation of blood B-HCG levels is not inconsistent with a diagnosis of pure seminoma and does not appear to influence adversely the outcome of radiotherapy.
 ...
PMID:The management of metastatic seminoma testis. 618 73

Serum AFP and HCG values were correlated with AFP and HCG tissue staining in 27 non-seminomatous germ cell tumors (NSGCT) of the testis and their retroperitoneal lymph node metastases after PVB chemotherapy. We found a poor correlation between tissue and serum AFP positivity and a moderately good correlation between tissue and serum HCG positivity in the testicular tumor. The therapy-related differentiated teratomatous elements did occasionally produce AFP or HCG, but AFP or HCG were not detectable in the patients' sera. These serum markers have no value for the detection of mature residual tumor following chemotherapy.
 ...
PMID:Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy. 618 32

Serum from seven of 15 patients with nonseminomatous testicular germ cell tumors impaired the transformation of lymphocytes from normal donors by phytohemagglutinin to less than 50% of that with addition to the cultures of normal AB serum. Similarly, serum from eight patients impaired the transformation by Staphylococcus aureus Cowan I. The impairment of the lymphocyte transformation did not correlate with the serum concentrations of alpha-fetoprotein (S-AFP) and human chorionic gonadotropin (S-HCG). The patients with metastases and serum that impaired lymphocyte transformation to less than 50% of that with addition of serum from the controls and the other patients survived in the same way (0.50 less than p less than 0.75, log-rank test). The prognosis of patients with testicular germ cell tumors seems not be influenced by S-AFP and S-HCG through an impact on lymphocyte functions determined as the response to the two mitogens.
 ...
PMID:Suppression of the mitogen response of normal lymphocytes by serum from patients with testicular germ cell tumors. 619 1


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>